Edwards(EW) Prnewswire·2024-11-04 14:00Lawsuit Overview - A securities class action lawsuit has been filed against Edwards Lifesciences Corporation (NYSE: EW) on behalf of investors who purchased or acquired Edwards securities between February 6, 2024, and July 24, 2024 [1] - The lead plaintiff deadline is December 13, 2024 [1] Alleged Misconduct - Defendants are accused of providing overly positive statements about the growth of Edwards' core product, Transcatheter Aortic Valve Replacement (TAVR), while allegedly concealing material adverse facts about the true state of the TAVR platform [3] - Edwards' claims were allegedly based on an overestimation of the low-treatment-rate patient population and the willingness of hospitals to continue using TAVR over newer treatment alternatives [3] Lead Plaintiff Process - Edwards investors may seek to be appointed as a lead plaintiff representative by December 13, 2024 [4] - The lead plaintiff acts on behalf of all class members and selects counsel to represent the class [4] Law Firm Information - Kessler Topaz Meltzer & Check, LLP is prosecuting the class action and encourages investors with significant losses to contact the firm for more information [5][6] - The firm has a global reputation for recovering billions of dollars for victims of fraud and corporate misconduct [6]